Search clinical trials for: AL3818 or placebo

Total 58227 results

Advenchen Laboratories, LLC

Active, not recruiting

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (APROMISS)

Leiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue Sarcoma

United States, United Kingdom, Spain, China, Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (ALTER0703)

Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (ALTER0303)

Non-small Cell Lung Cancer

China
Advenchen Laboratories, LLC

Available

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Gynecologic Cancer | Sarcoma,Soft Tissue
Shanghai Zhongshan Hospital

Withdrawn

Adjuvant Therapy With Anlotinib for HCC

Hepatocellular Carcinoma

China
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital; Yan'an University Affiliated Hospital

Unknown

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing... and other collaborators

Unknown

Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy

Soft Tissue Sarcoma

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Unknown

Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

Advanced Solid Tumor | Advanced/Metastatic Colorectal Cancer

China
Allergan

Terminated

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

Fibromyalgia

Switzerland, United States, United Kingdom
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
Allergan

Terminated

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

Irritable Bowel Syndrome

United States
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Allergan

Completed

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful

United States
Huashan Hospital

Active, not recruiting

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

Malignant Glioma

China
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
Ruijin Hospital

Recruiting

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Soft Tissue Sarcoma | Radiotherapy | Anlotinib | High Risk of Recurrence

China
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Hospital Ambroise Paré Paris

Completed

Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain

Lumbar Radiculopathy

France
Arthrosi Therapeutics

Completed

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Healthy Volunteers

Australia
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A First-in-Human Study of QY211 Gel in Adult Subjects

Atopic Dermatitis

China
HK inno.N Corporation

Unknown

A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects

Healthy

Korea, Republic of
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer

China
Creabilis SA
LCG Bioscience

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

Safety
Intron Biotechnology, Inc.

Completed

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

Acute Radiation Syndrome

Korea, Republic of
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Ji Xing Pharmaceuticals Australia Pty Ltd
Novotech (Australia) Pty Limited

Recruiting

JX09 SAD/MAD in Healthy Participants

Resistant Hypertension

Australia
aTyr Pharma, Inc.
Foundation for Sarcoidosis Research

Completed

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States
AceLink Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers

Autosomal Dominant Polycystic Kidney

Australia
Ali Amini Harandi

Unknown

MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code) (MLC901)

Traumatic Brain Injury

Iran, Islamic Republic of
Genexine, Inc.

Completed

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Autoimmune Diseases

Korea, Republic of
Green Cross Corporation
Korean Center for Disease Control and Prevention

Completed

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (GC1109)

Anthrax

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Completed

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Advanced Solid Tumors

China
Shi Yuankai

Recruiting

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Head and Neck Squamous Cell Carcinoma

China
Hanmi Pharmaceutical Company Limited

Completed

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Healthy

United States
Creabilis SA
Aalborg University Hospital

Completed

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Neuropathic Pain

Denmark
Juventas Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

Critical Limb Ischemia

United States, India
Devintec Sagl
Meditrial SrL

Recruiting

Devintec OR-AT0222 Oral Gel for the Treatment of Canker Sores: A Double Blind, Randomized, Placebo Controlled Clinical Investigation

Recurrent Aphthous Ulcer

Italy
Newsoara Biopharma Co., Ltd.

Unknown

Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

Healthy

China
Unity Biotechnology, Inc.

Terminated

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

Knee Osteoarthritis

United States
JULIANA AQUINO DE MOURA

Completed

The Effect of Non-hormonal Gel Application in Women in the Menacme With Sexual Dysfunction

Sexual Dysfunction
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Developing Oral LT3 Therapy for Heart Failure - HFrEF (DOT3HF-HFrEF)

Heart Failure With Reduced Ejection Fraction | Low Triiodothyronine Syndrome

United States
Massachusetts General Hospital

Withdrawn

Characterization of the Pharmacodynamic Response to Vaped THC

Vaping | THC

Search clinical trials for: AL3818 or placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations